Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-12-16

Clinical Trial Update: A Study of YPEG-rhEPO in Patients Suffered From Anemia Due to Chronic Kidney Disease [Phase 2]

View source ↗

Summary

Phase 2 trial update for YPEG-rhEPO in patients with anemia due to chronic kidney disease has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • YPEG-rhEPO (YPEG-rhEPO)

Snippet

Sponsor: Xiamen Amoytop Biotech Co., Ltd. | Conditions: Renal Anemia of Chronic Kidney Disease | Phase 2 | Status: COMPLETED